Home›Trial›NCT07090161
NCT07090161Phase 2RECRUITING

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Study Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Conditions
HypertensionUncontrolled Hypertension
Interventions / Drugs
iloperidonePlacebo
View on ClinicalTrials.gov ↗
Sponsor
VNDA
Vanda Pharmaceuticals
Neuroscience
D41/100
Study Details
Enrollment240 participants
Primary Completion—
Lead SponsorVanda Pharmaceuticals
Data Retrieved2026-04-11 04:31:05.188736+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 240 participants
Sponsor Catalyst Profile

Vanda Pharmaceuticals (VNDA) is the sponsoring company for this trial. BiotechSign currently grades this company D (41/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

VNDA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.